

SUPPLEMENTARY APPENDIX

Supplementary methods

Prior to each infusion (within 1-3 hours), patients received acetaminophen (650-1,000 mg IV or oral [PO]), diphenhydramine (25-50 mg IV or PO), and methylprednisolone (100 mg IV or PO; optional reduction to 60 mg after the second infusion); montelukast (10 mg PO) was administered prior to infusion on Cycle 1 Day 1. Patients also received oral methylprednisolone 20 mg (or equivalent) on the first 2 days following all daratumumab infusions. In the absence of infusion-related adverse events after the first 3 infusions, post-infusion corticosteroids were administered at the investigators' discretion. Patients were carefully observed during infusions for the development of infusion-related reactions, which were managed by treatment interruption, reduced infusion rate, treatment discontinuation, or medical intervention. The administration of concomitant therapy or other interventions to provide supportive care (eg, growth factors) was permitted and prophylaxis for herpes zoster reactivation was recommended during the treatment phase.